VERAXA Biotech (NASDAQ: VRXA) unveiled the first in vivo proof-of-concept data for its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego, a disclosure that carries significant implications for the company's pipeline and for the broader antibody-drug conjugate field. According to NEWMEDIAWIRE, the study showed significant tumor regression in a breast cancer model after a single 3 mg/kg dose, with no observed decrease in body weight.
The in vivo results are the first demonstration that the platform works in a living organism, not just in cell cultures. The data also revealed that both components of the BiTAC-ADC were required to produce the intended tumor-specific response. This requirement is central to the platform's design: it suggests the therapy is engineered to activate only when both targeting elements engage, potentially limiting off-target effects.
Additional in vitro studies reinforced this mechanism. The platform distinguished cancer cells from healthy cells, prevented the release of active toxins outside the tumor, and targeted multiple cancer cell lines. Together, the findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity. For patients, that could mean fewer side effects from potent cytotoxic payloads that often damage healthy tissue.
For investors, the announcement marks a transition from preclinical concept to tangible in vivo validation. VERAXA, an emerging leader in designing novel cancer therapies, is building a pipeline of ADCs and proprietary BiTAC formats. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL). As a clinical-stage milestone, first in vivo proof-of-concept is often a key inflection point for early-stage biotechs, and the breast cancer regression data provide a foundation for advancing BiTAC-ADCs toward clinical development.
The full press release is available at https://ibn.fm/cs8SW, and additional information on VERAXA Biotech (NASDAQ: VRXA) can be found at VERAXA Biotech (NASDAQ: VRXA). The company's latest news and updates are available in its newsroom at https://ibn.fm/VRXA. Forward-looking statements in the release are subject to risks and uncertainties described in the company's SEC filings.
